Source record
melanotan: a cyclic alpha-MSH analog studied across four research domains from 1989 to 2026
26 primary findings indexed. Phase I human data available for pigmentation and erectile function. Serious adverse events documented in case reports. One approved analog (afamelanotide). Zero approved indications for MT-II.
What Is Melanotan?
melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH): Melanotan I (afamelanotide, a linear 13-amino-acid analog) and Melanotan II (a cyclic 7-amino-acid analog). Both were developed at the University of Arizona by Hruby and Hadley beginning in the late 1980s as truncated, cyclized, enzymatically resistant derivatives of the endogenous alpha-MSH tridecapeptide [1].
The original research rationale was photoprotection: if a synthetic alpha-MSH analog could drive melanin production in human skin, it might reduce UV-induced DNA damage and lower skin cancer incidence [1]. That rationale produced three decades of published research, two approved compounds (afamelanotide for erythropoietic protoporphyria; bremelanotide/PT-141 for hypoactive sexual desire disorder), and a persistent unapproved compound — Melanotan II — still studied but approved nowhere [2].
Melanotan II binds non-selectively to melanocortin receptors 1, 3, 4, and 5 (MC1R–MC5R). MC1R activation drives melanogenesis — the cAMP/PKA/CREB/MITF cascade that upregulates tyrosinase and shifts melanin synthesis toward the darker eumelanin form [4]. MC4R activation in the central nervous system mediates appetite suppression, the erectogenic effect, and the autonomic side effects (nausea, yawning) observed in early human trials [5][6][7].
This site is a drill-down index of that literature. Every quantitative finding is cited. Every adverse event is documented. The melanotan research literature begins with the melanogenesis mechanism; the melanotan dosage research section documents what Phase I trials actually studied; the melanotan side effects record covers the case reports of renal infarction, rhabdomyolysis, dysplastic nevi, and mucosal melanoma. The full reference list is at /references.
Melanotan II vs. Melanotan I: How the Two Analogs Differ
Melanotan I (afamelanotide) is a linear 13-amino-acid analog with preferential MC1R selectivity. Melanotan II is a cyclic 7-amino-acid heptapeptide (Cyclo(His-Phe-Arg-Trp-Gly), MW 1024.2 Da) with broader MC1R/MC3R/MC4R/MC5R activity. The cyclization of MT-II improved its metabolic stability and receptor potency relative to MT-I — and expanded its biological footprint beyond pigmentation into appetite suppression, sexual behavior, and neuroprotection [2].
The practical divergence: MT-I's MC1R selectivity made it a clean photoprotection candidate with a manageable adverse-event profile. EU approval (Scenesse, 2014) and FDA approval (2019) followed for erythropoietic protoporphyria [15]. MT-II's broader receptor activity produced measurable erectogenic and anorexigenic effects — findings that proved commercially valuable when Palatin Technologies isolated MT-II's MC4R-active descendant bremelanotide (PT-141), which received FDA approval in 2019 (bremelanotide) for hypoactive sexual desire disorder in premenopausal women [19]. MT-II itself has no approved indication in any jurisdiction.
The Melanotan I vs. Melanotan II distinction matters for interpreting the literature: not all findings for afamelanotide transfer to MT-II, and not all MT-II adverse events have been observed with MT-I.
What Is Melanotan Made Of?
Melanotan II is a fully synthetic peptide — not derived from biological sources. It is produced by solid-phase peptide synthesis from standard amino acid precursors. The compound consists of seven amino acids in a cyclic arrangement: Cyclo(His-Phe-Arg-Trp-Gly), with an amide bond forming the cyclic bridge. Molecular weight: 1024.2 Da [1].
Lyophilized (freeze-dried) MT-II powder is the standard research form. Oral bioavailability in rats is 4.6% — low enough that subcutaneous injection is the standard research and clinical route [1]. The cyclic structure provides substantially better enzymatic stability than the linear alpha-MSH precursor, which is why MT-II remains bioactive at doses far lower than native alpha-MSH.
Research Applications of Melanotan II
Published research has investigated Melanotan II across four distinct domains:
Pigmentation and melanogenesis. The original rationale. Phase I data showed measurable pigmentation increases in human subjects without UV exposure [3]. The mechanism — MC1R activation of the cAMP/PKA/CREB/MITF/tyrosinase cascade — is well established [4].
Erectile dysfunction. The most extensively studied human application. Two double-blind, placebo-controlled crossover trials in psychogenic and organic ED demonstrated erectogenic effects at 0.025 mg/kg subcutaneous [5][6][7]. The MC4R mechanism, not MC1R, mediates this effect.
Appetite suppression and energy balance. Rodent studies using central (ICV) infusion showed acute anorexic effects and sustained body-mass reduction via MC4R [8][9]. A 2022 mouse study confirmed selective appetite suppression via mesolimbic MC4R in the nucleus accumbens without aversive effects or metabolic rate changes [10].
Neuroprotection. A rat study found that MT-II at 20 µg/kg subcutaneous promoted peripheral nerve regeneration after sciatic crush injury and partially protected against cisplatin-induced toxic neuropathy — with a bell-shaped dose-response indicating the middle dose was effective while lower and higher doses were not [21].
Review the frequently asked questions about melanotan for compound-specific questions, or the melanotan research literature for mechanism detail.
Melanotan II Research in Male Subjects
Three human trials enrolled male subjects for MT-II. In the 1996 pilot Phase I study, 3 healthy males received 5 low-dose injections (0.01–0.03 mg/kg/day); measurable pigmentation increases appeared in 2 of 3, and spontaneous penile erections lasting 1–5 hours post-injection were an incidental finding [3].
A 1998 double-blind crossover trial in 10 men with psychogenic ED found 0.025 mg/kg produced erections in 8 of 10 subjects; mean tip rigidity >80% lasted 38 minutes vs. 3 minutes for placebo (p=0.0045) [5]. A 2000 trial in 20 men with organic ED replicated this: 17 of 20 subjects had erections; increased sexual desire followed 68% of active doses vs. 19% of placebo [6]. A second 2000 trial in 10 men with organic ED confirmed erection duration ~45 minutes with active drug vs. 1.9 minutes for placebo [7].
The erections produced by MT-II in these trials occurred without visual sexual stimulation — a finding that localizes the mechanism to central MC4R signaling rather than peripheral vascular effects.